Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

V5514

Sigma-Aldrich

Anti-Vasopressin V2 Receptor antibody produced in rabbit

affinity isolated antibody, buffered aqueous solution

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Número MDL:
MFCD06798554
Código UNSPSC:
12352203
NACRES:
NA.41

origen biológico

rabbit

Nivel de calidad

200

conjugado

unconjugated

forma del anticuerpo

affinity isolated antibody

tipo de anticuerpo

primary antibodies

clon

polyclonal

formulario

buffered aqueous solution

reactividad de especies

human

técnicas

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 3 μg/mL using human kidney

Nº de acceso UniProt

P30518

Condiciones de envío

dry ice

temp. de almacenamiento

−20°C

Información sobre el gen

human ... AVPR2(554)
mouse ... Avpr2(12000)
rat ... Avpr2(25108)

Inmunógeno

Synthetic peptide corresponding to the N-termal extracellular domain of human vasopressin V2 receptor. The immunizing peptide has 67% homology with the rat and mouse gene.

Aplicación

Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Immunohistochemistry (1 paper)

Acciones bioquímicas o fisiológicas

Vasopressin V2 receptor is a G-protein-coupled receptor that binds to the peptide hormone arginine vasopressin produced by posterior pituitary gland. The V2 receptor stimulates the production of cyclic AMP, controls the water reabsorption and salt balance by the kidneys. Antagonists to the V2 receptor have applications in the treatment of congestive heart failure, hypertension, hyponatremia and excessive water retention.

Forma física

Solution in phosphate buffered saline containing 0.1% sodium azide.

Cláusula de descargo de responsabilidad

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Código de clase de almacenamiento

10 - Combustible liquids

Clase de riesgo para el agua (WGK)

nwg

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Juan Garona et al.
Clinical & experimental metastasis, 33(6), 589-600 (2016-05-06)
[V(4)Q(5)]dDAVP is a novel 2nd generation vasopressin analogue with robust antitumour activity against metastatic breast cancer. We recently reported that, by acting on vasopressin V2r membrane receptor present in tumour cells and microvascular endothelium, [V(4)Q(5)]dDAVP inhibits angiogenesis and metastatic progression
Shuai Mu et al.
Molecules (Basel, Switzerland), 19(2), 2694-2706 (2014-02-26)
Twenty-one non-peptide substituted desloratadine class compounds were synthesized as novel arginine vasopressin receptor antagonists from desloratadine via successive acylation, reduction and acylation reactions. Their structures were characterized by 1H-NMR and HRMS, their biological activity was evaluated by in vitro and
Abeda Jamadar et al.
International journal of molecular sciences, 23(14) (2022-07-28)
Vasopressin type-2 receptor (V2R) is ectopically expressed and plays a pathogenic role in clear cell renal cell carcinoma (ccRCC) tumor cells. Here we examined how V2R signaling within human ccRCC tumor cells (Caki1 cells) stimulates stromal cancer-associated fibroblasts (CAFs). We
Natasha Tatiana Sobol et al.
Experimental and therapeutic medicine, 21(6), 566-566 (2021-04-15)
Osteosarcoma is the most prevalent primary bone malignancy. Due to its high aggressiveness, novel treatment strategies are urgently required to improve survival of patients with osteosarcoma, especially those with advanced disease. Desmopressin (dDAVP) is a widely used blood-saving agent that
[Human recombinant alpha-2b interferon (Introna). Intralesional treatment of therapy-resistant condylomata acuminata].
C S Petersen et al.
Ugeskrift for laeger, 149(24), 1594-1595 (1987-06-08)
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico